DBG Health has announced the appointment of Matt Zeller as Chief Executive Officer of Arrotex Pharmaceuticals, the pharmaceutical and biological business of DBG Health.

An experienced global pharmaceutical leader with more than 20 years’ experience, most recently with Novartis, Zeller (pictured) said he was honoured to join the Arrotex team as CEO.

“The scale of the DBG business, its entrepreneurial culture, the calibre of its people, and its clarity of purpose around supporting Australian patients and families are all central to why I’m so excited to join,” he said.

Zeller started the role this week and reports in to Dennis Bastas, Founder and Group CEO of DBG Health.

“We are delighted to welcome Matt as CEO of Arrotex Pharmaceuticals at such an important time for our business,” Bastas said.

“Matt is a proven global pharmaceutical executive, and he is exceptionally well-placed to help lead the next phase of growth for Arrotex and DBG Health,” he added.

The post Arrotex CEO appointment appeared first on Pharmacy Daily.